Completed PHASE1 INTERVENTIONAL 2-arm NCT03022175

A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers

A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR741 in Healthy Volunteers

Sponsor: CPR Pharma Services Pty Ltd, Australia

Conditions Healthy Volunteers

Interventions Placebo SPR741

Updated 6 times since 2017 Last updated: Oct 4, 2017 Started: Dec 31, 2016 Primary completion: Jul 31, 2017 Completion: Sep 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03022175, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by CPR Pharma Services Pty Ltd, Australia, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Oct 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Feb 2017 — Oct 2017 [monthly]

Recruiting PHASE1

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CPR Pharma Services Pty Ltd, Australia
Spero Therapeutics

Data source: Spero Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia